Zetagen Therapeutics Secures Composition-of-Matter Patents from USPTO for Novel Breast Cancer Platform

July 28, 2025, (Syracuse, New York) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via intratumorally administration, for primary and metastatic breast cancers, announced today they have successfully secured the foundational Composition-of-Matter patents and claims from the USPTO for their proprietary breast cancer platform.

Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast™ (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases

June 17, 2025, (Syracuse, New York)— Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing first-of-its-kind targeted therapies for primary and metastatic breast cancer, announced today the peer-reviewed publication in PLOS-One of their dose optimization in-vivo study results of ZetaMast™ (Zeta-MBC-005).

Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer

May 6, 2025, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic and primary breast cancers, announced today they have successfully completed enrollment in their phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions (ClinicalTrials.gov #NCT05280067).

Zetagen Therapeutics Expands IP Portfolio, Achieving a Milestone of 64 Worldwide Patents in 2024

January 8, 2025, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates, announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the United States, Europe, Canada, Australia, Japan, United Kingdom, India, Sweden and Switzerland.

Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST™ (Zeta-MBC-005) Metastatic Breast Cancer in Liver

December 10, 2024, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, minimizing patient side effects with the potential to increase survival rates, announced today in-vivo results of their dose optimization study of ZetaMAST™ (Zeta-MBC-005). Zetagen identified two concentrations of Zeta-MBC-005 which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin.

Zetagen Therapeutics Announces First Patients Enrolled in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer

November 12, 2024, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic breast cancer to bone and soft tissues, announced today that the first two patients have enrolled in the phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions (ClinicalTrials.gov #NCT05280067).

New Data Published in JAAOS Demonstrates Breakthrough Therapy ZetaFuse® as a Potential Treatment for Degenerative Disc Disease in Late-Stage Cancer Patients

September 24, 2024, (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs, today announced publication of clinical data in the peer-reviewed Journal of the American Academy of Orthopaedic Surgeons (JAAOS) on ZetaFuse® (Zeta-ZF-002) for the treatment of multi-level DDD in a Stage 4 lung cancer patient.

Zetagen Announces the Appointment of Debasish (Debu) Tripathy M.D. to its Advisory Board

March 18, 2024, (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for the treatment of metastatic and primary cancers in bone and soft tissue organs, today announced the appointment of Debasish (Debu) Tripathy, MD to its advisory board. Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Press Releases

Recent news published by Zetagen